

Amendments to the Claims

1. (Currently Amended) A method of ~~managing~~, treating or ameliorating a respiratory infection, or a symptom thereof, in a human subject suffering therefrom, said method comprising administering to said human subject an effective amount of an IL-9 antagonist.
2. (Canceled)
3. (Currently Amended) A method of ~~preventing, managing~~, treating or ameliorating wheezing in a human pre-term infant, a human infant or a human child, said method comprising administering to said pre-term infant, infant or child an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof antagonist comprises:
 - (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or
 - (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28.
4. (Currently Amended) A method of ~~preventing, managing~~, treating or ameliorating wheezing in a human subject suffering therefrom, said method comprising administering to said human subject;
an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof antagonist comprises:
 - (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or
 - (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28, and

an effective amount of at least one other therapy that is not administration of an IL-9 antagonist.

5. (Currently Amended) A method of ~~preventing, managing,~~ treating or ameliorating asthma or an allergy, or one or more symptoms thereof, in a human subject suffering therefrom, said method comprising administering to said human subject:

an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof antagonist comprises:

(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28, and

an effective amount of at least one other asthma or allergy therapy.

6-7. (Canceled)

8. (Currently Amended) The method of claim 1, 2 or 3 further comprising administering an effective amount of at least one other therapy that is not administration of an IL-9 antagonist.

9. (Original) The method of claim 1, wherein the respiratory infection is a viral infection, a bacterial infection or a fungal infection.

10. (Original) The method of claim 9, wherein the viral infection is a parainfluenza virus infection, an influenza virus infection or a metapneumovirus infection.

11. (Withdrawn) The method of claim 9, wherein the viral infection is a respiratory syncytial virus (RSV) infection.

12-14. (Canceled)

15. (Original) The method of claim 8, wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator.
16. (Currently Amended) The method of claim 11 ~~or 14~~ further comprising administering to said subject an effective amount of an anti-RSV antigen antibody.
17. (Original) The method of claim 16, wherein the anti-RSV antigen antibody is palivizumab.
18. (Currently Amended) The method of claim 1, ~~2~~ or 3 further comprising administering a leukotriene modifier.
19. (Original) The method of claim 18, wherein the leukotriene modifier is montelukast, zafirlukast, pranlukast or zileuton.
20. (Original) The method of claim 4 or 5, wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator.
21. (Original) The method of claim 4 or 5 further comprising administering to said subject a leukotriene modifier, an anti-histamine, an anti-IgE antibody, an anti-IL-4 antibody or a mast cell protease inhibitor.
22. (Original) The method of claim 16 further comprising administering a leukotriene modifier.
23. (Currently Amended) The method of claim 1, ~~2, 3, 4 or 5~~, wherein the antibody or fragment thereof is IL-9 antagonists ~~are~~ administered parenterally, orally or intranasally.
24. (Original) The method of claim 1, wherein the subject is a pre-term infant, an infant, a child or an elderly person.
25. (Original) The method of claim 1, wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency.
26. (Canceled)

27. (Original) The method of claim 4 or 5, wherein the subject is a pre-term infant, an infant, a child or an elderly person.
28. (Original) The method of claim 4 or 5, wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency.
- 29-36. (Canceled)
37. (New) The method of claim 1 wherein the IL-9 antagonist is an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof comprises:
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or
 - (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28.
38. (New) The method of claim 37 wherein the antibody or fragment thereof is administered parenterally, orally or intranasally.
39. (New) The method of claim 37 wherein the subject is a pre-term infant, an infant, a child or an elderly person.
40. (New) The method of claim 37, wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency.